arrow
M

Marc Tischkowitz

University of Cambridge
H指数:89
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ERN GENTURIS cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome (PHTS)

ERNGENTURIS癌症监测指南:针对PTEN错构瘤肿瘤综合征(PHTS)个体的监测指南

2026-07-160
PREAI
CanRisk-GP protocol: A feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice

CanRisk-GP协议:一项将前瞻性多因素乳腺癌风险评估纳入全科实践的可行性研究

2025-11-260
PRE
Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

398,238名女性的全基因组关联研究揭示了七个与高级别浆液性卵巢癌相关的位点

2025-11-200
OAAI
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes

BRCA1-、BRCA2-和PALB2相关的范可尼贫血:扩展疾病表型特征并预测杂合子乳腺癌风险的潜力

2025-10-300
PRE
Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

RAD51C、RAD51D和BRIP1基因杂合性胚系致病性变异携带者的管理:美国医学遗传学与基因组学学院(ACMG)的临床实践资源

2025-10-070
PRE
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants

ACMG/AMP变异整理指南中关于体细胞PALB2序列变异分析的规定

2025-09-170
OAAI
Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population

将BOADICEA乳腺癌和卵巢癌风险模型适应于英国多民族人口

2025-07-170
OAAI
Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations

基于临床-公共卫生效用的主流肿瘤学中乳腺癌胚系多基因-panel检测:ESMO精准肿瘤学工作组建议

2025-06-150
PREAI
The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)

PTEN错构瘤综合征(PHTS)中第二原发癌的风险

2025-05-240
OAAI
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE

BRCA1和BRCA2致病性变异携带者与非携带者自然绝经年龄、月经初潮年龄、月经周期长度、身高和BMI的分布:EMBRACE研究的结果

2025-05-210
OA
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Abraham, J.E.; O’Connor, L.O.; Grybowicz, L.; Alba, K.P.; Dayimu, A.; Demiris, N.; Harvey, C.; Drewett, L.M.; Lucey, R.; Fulton, A.; et al. 新辅助PARP抑制剂在BRCA1和BRCA2相关乳腺癌中的用药方案:PARTNER,一项随机II/III期临床试验。Nat. Commun. 2025, 16, 4269. [Google Scholar] [CrossRef] [PubMed]

2025-05-130
OAAI
UK clinical practice guidelines for the management of patients with constitutional POT1 pathogenic variants

英国临床实践指南:针对携带体细胞POT1致病性变异患者的管理

2025-05-110
PRE
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records

BRCA1和BRCA2致病性变异携带者中,有乳腺癌病史者行双侧输卵管卵巢切除术的长期健康结局:一项基于关联电子健康记录的回顾性队列研究

2025-05-080
OA
Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model (vol 34, pg 205, 2025)

将替代多基因风险评分纳入BOADICEA乳腺癌风险预测模型 (第34卷,205页,2025)

2025-01-090
OAAI
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)

使用癌症表型性别特异性来实现对卵巢小细胞癌,高钙血症型 (SCCOHT) 的SMARCA4致病变体的无偏外显率估计

2025-01-010
PRE
Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

ATM杂合性胚系致病性变异个体的管理:美国医学遗传学与基因组学学院(ACMG)的临床实践资源

2025-01-011
PRE